

# UCSF

## UC San Francisco Previously Published Works

### Title

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

### Permalink

<https://escholarship.org/uc/item/8w4003z6>

### Journal

The Lancet Neurology, 18(12)

### ISSN

1474-4422

### Authors

Nalls, Mike A  
Blauwendraat, Cornelis  
Vallerga, Costanza L  
[et al.](#)

### Publication Date

2019-12-01

### DOI

10.1016/s1474-4422(19)30320-5

Peer reviewed



Published in final edited form as:

*Lancet Neurol.* 2019 December ; 18(12): 1091–1102. doi:10.1016/S1474-4422(19)30320-5.

## Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-genome wide association study

A full list of authors and affiliations appears at the end of the article.

### SUMMARY

**Background**—Genome-wide association studies (GWASs) in Parkinson's disease (PD) have increased the scope of biological knowledge about the disease over the past decade. We sought to use the largest aggregate of GWAS data to identify novel risk loci and gain further insight into disease etiology.

**Methods**—We performed the largest meta-GWAS of PD to date, involving the analysis of 7.8M SNPs in 37.7K cases, 18.6K UK Biobank proxy-cases (having a first degree relative with PD), and 1.4M controls. We carried out a meta-analysis of this GWAS data to nominate novel loci. We then evaluated heritable risk estimates and predictive models using this data. We also utilized large gene expression and methylation resources to examine possible functional consequences as well as tissue, cell type and biological pathway enrichments for the identified risk factors. Additionally we examined shared genetic risk between PD and other phenotypes of interest via genetic correlations followed by Mendelian randomization.

**Findings**—We identified 90 independent genome-wide significant risk signals across 78 genomic regions, including 38 novel independent risk signals in 37 loci. These 90 variants explained 16–36% of the heritable risk of PD depending on prevalence. Integrating methylation and expression data within a Mendelian randomization framework identified putatively associated genes at 70 risk signals underlying GWAS loci for follow-up functional studies. Tissue-specific expression enrichment analyses suggested PD loci were heavily brain-enriched, with specific neuronal cell types being implicated from single cell data. We found significant genetic correlations with brain volumes, smoking status, and educational attainment. Mendelian randomization between cognitive performance and PD risk showed a robust association.

---

<sup>CA</sup> denotes corresponding author, mike@datatecnica.com.

\* denotes shared first authorship.

#### AUTHOR CONTRIBUTIONS

Study level analysis

MAN, CB, CLV, KH, SB-C, DC, MT, DK, LR, JS-S, LK, LP, ABS

Additional analysis and data management

MAN, CB, SB-C, AJN, AX, JY, JG, PMV, ABS

Design and funding

MAN, CB, CLV, KH, SB-C, LP, MS, KM, MT, AB, JY, ZG-O, TG, PH, JMS, NW, DAH, JH, HRM, JG, PMV, RRG, ABS

Critical review and writing the manuscript

MAN, CB, CLV, KH, SB-C, DC, MT, DAK, AJN, AX, JB, EY, RvC, JS-S, CS, MS, LK, LP, AS, HI, HL, FF, JRG, DGH, SWS, JAB, MM, OAA, J-CC, SL, JJ, LMS, MS, PT, KM, MT, AB, JY, ZG-O, TG, PH, JMS, NW, DAH, JH, HRM, JG, PMV, RRG, ABS

All others have no disclosures or potential conflicts of interest.

Full consortia membership (PubMed indexed) is available in the supplemental materials (Text S1).

**Interpretation**—These data provide the most comprehensive understanding of the genetic architecture of PD to date by revealing many additional PD risk loci, providing a biological context for these risk factors, and demonstrating that a considerable genetic component of this disease remains unidentified.

---

## INTRODUCTION

Parkinson's disease is a neurodegenerative disorder, affecting approximately 1 million individuals in the United States alone (5). PD patients suffer from a combination of progressive motor and non-motor symptoms affecting daily function and quality of life. The prevalence of PD is projected to double in some age groups by 2030, creating a substantial burden on healthcare systems (5).

Early investigations into the role of genetic factors in PD focused on the identification of rare mutations underlying familial disease, (6,7) over the past decade there has been a growing appreciation for the contribution of genetics in sporadic disease(1,8). Genetic studies of sporadic PD have altered the foundational view of disease etiology.

We executed a series of experiments to explore the genetics of PD (summarized in Figure 1). We performed the largest-to-date GWAS for PD, including 7.8M SNPs, 37.7K cases, 18.6K UK Biobank (UKB) “proxy-cases” (individuals without PD that have a family history of PD) and 1.4M controls. We identified mechanistic candidate genes for PD, providing valuable therapeutic targets. We assessed the function of these potential risk genes via Mendelian randomization, expression enrichment, and protein-protein interaction network analysis. We estimated PD heritability, developed a polygenic risk score that predicted a substantial proportion of this heritability, and leveraged these results to inform future studies. Finally, we identified candidate PD biomarkers and risk factors using genetic correlation and Mendelian randomization.

## SUMMARY OF METHODS

### GWAS Study design and risk locus discovery

Three sources of data were used for discovery analyses, these include three previously published studies, 13 new datasets, and proxy-case data from the UK BioBank (UKB). Previous studies include summary statistics published in Nalls *et al.* 2014, GWAS summary statistics from the 23andMe Web-Based Study of Parkinson's Disease (PDWBS) in Chang *et al.* 2017, and the publicly available NeuroX dataset from the International Parkinson's Disease Genomics Consortium (IPDGC) previously used previously as a replication sample. These cohorts have been reported in detail (1,9). We included 13 new case-control sample series for meta-analyses through either publicly available data or collaborations (please see Supplementary Table S1 for details regarding these studies). All samples from the 13 new datasets underwent similar standardized quality control for inclusion, mirroring that of previous studies. We attempted to generate summary statistics for GWAS meta-analyses as uniformly as possible. This analysis utilized fixed-effects meta-analyses as implemented in METAL to combine summary statistics across all sources (10).

### Conditional-joint analysis to nominate variants of interest

To nominate variants of interest, we employed a conditional and joint analysis strategy (COJO, <http://cns.genomics.com/software/gcta/>) to algorithmically identify variants that best account for the heritable variation within and across loci (11). Additional analyses described below were utilized to further scrutinize putative associated variants and account for possible differential linkage disequilibrium (LD) signatures, including using the massive single site reference data from 23andMe in more conditional analyses. If a variant nominated during the COJO phase of analysis was greater than 1Mb from any of the genome-wide significant loci nominated in Chang *et al.* 2017, we considered this to be novel. We defined nominated risk variants as from a single locus if they were within  $\pm 250$ kb of each other. We instituted two filters after fixed-effects and COJO analyses, excluding variants that 1) had a random-effects P value across all datasets  $> 4.67E-04$  and 2) a conditional analysis  $P > 4.67E-04$  using participant level 23andMe genotype data. Please see Supplementary Table S2 summarizing all variants nominated plus the Methods and Results Supplement.

### Refining heritability estimates and determining extant genetic risk

We used the R package PRSice2 for risk profiling (12), this carries out polygenic risk score (PRS) profiling in the standard weighted allele dose manner (1,9,13–15). In addition, PRSice incorporates permutation testing where case and control labels are swapped in the withheld samples to generate an empirical P. This workflow identifies the best P thresholds for variant inclusion while carrying out LD pruning. In many cases this best P threshold for PRS construction does not meet what is commonly regarded as genome-wide significance.

A two stage design was also employed, training on the largest single array study (NeuroX-dbGaP) and then tested on the second largest study (HBS) using the same array. These two targeted array studies were chosen for three reasons: precedent in the previous publications where the NeuroX-dbGaP dataset was used in PRS; direct genotyping of larger effect rare variants in *GBA* and *LRRK2*; participant level genotypes for these datasets are publicly available.

To calculate heritability in clinically defined PD datasets, we used LD score regression (LDSC) employing the LD references for Europeans provided with the software (16). This workflow was also repeated on a per cohort level (see Supplementary Appendix).

### Functional causal inferences via Quantitative Trait Loci (QTL)

We used MR to test whether changes in DNA methylation and/or RNA expression of genes physically proximal to significant PD risk loci were causally related to PD risk. To nominate genes of interest for MR analyses, we took our putative 90 loci in the large LD reference used for the COJO phase of analysis and identified SNPs in LD with our SNPs at an  $r^2 > 0.5$  within  $\pm 1$ MB (Supplementary Table S5). MR was used by integrating discovery phase summary statistics with quantitative trait locus (QTL) association summary statistics across well-curated methylation and expression datasets. We used the curated versions of Qi *et al.*, 2018 brain methylation and expression summary statistics (multi-study and multi-tissue meta-analysis), as well as a specific focus on substantia nigra data (GTEx), we made use of the blood expression data from Vösa *et al.* 2018 (eQTLGen, all available here

<http://cnsgenomics.com/software/smr/#Overview> and here <http://www.eqtngen.org> (17–21). For all QTL analyses, we utilized the multi-SNP summary-based Mendelian randomization (SMR) method as a framework to carry out MR. All MR effect estimates are reported on the scale of a standard deviation increase in the exposure variable relating to a similar change in PD risk. Simply, these MR analyses compare the local polygenic risk of an exposure (methylation or expression) to similar polygenic risk in an outcome (PD), inferring causal associations under the assumption that there is no intermediate confounder associated with both parameters and that the association is not simply due to LD.

To further investigate expression enrichment across cell types in PD, we integrated GWAS summary statistics with expression and network data from the FUMA webserver (<https://fuma.ctglab.nl/>, version 1.3.1) (22).

### Rare coding variant burden tests

A uniformly quality controlled and imputed dataset from the IPDGC was used to carry out burden tests for all rarer coding variants successfully imputed in an average of 85% of the sample series (17,188 cases and 22,875 controls). These analyses include all variants at a hard call threshold of imputation quality > 0.8. After annotation with annovar, we had a total of 37,503 exonic coding variants (nonsynonymous, stop or splicing) at MAF < 5% and a subset of 29,016 at MAF < 1% (23). For inclusion in this phase, a gene must have contained at least 2 coding variants. After assembling this subset of 113 testable genes, we used the optimized sequence kernel association test to generate summary statistics at maximum MAFs of 1% and 5% (24).

### LD score regression and causal inference

To investigate correlations of PD genetics with that of multiple traits and diseases, we employed bivariate LDSC (16). These analyses were carried out using data from the 757 GWAS available via LD Hub and biomarker GWAS summary statistics on c-reactive protein and cytokine measures; LD Hub was accessed on June 20th, 2018 (version 1.2.0) (25–27). P values from the bivariate LDSC were adjusted for FDR to account for multiple testing. Traits showing significant genetic correlations with PD were analyzed using MR methods. We excluded the UKB data when a nominated trait was from summary statistics derived from the UKB or if the UKB was included as part of a meta-analysis.

When complete GWAS summary statistics were available for traits of interest (relating to smoking and education), we used the more powerful bi-directional generalized summary-data-based Mendelian Randomization (GSMR). We analyzed GWAS summary statistics for smoking initialization (453,693 records from a self-report survey with 208,988 regular smokers and 244,705 never regular smokers) and current smoking (CS) within the UKB, CS contrasted 47,419 current smokers versus 244,705 never regular smokers. The same analysis was carried out incorporating recent GWAS data regarding educational attainment (N = 766,345) from self report in the UK and cognitive performance (N = 257,828) as measured by the *g* composite score (28). These were analyzed using methods to mirror that of the UKB PD GWAS dataset. Combined left and right putamen volume from a T2 magnetic resonance imaging GWAS available from Oxford Brain Imaging Genetics (BIG) Server

(accessed December 28th, 2018) (29). All MR analyses included GWAS on the scale of tens of thousands of samples and overcame the considerable power demands of the methodology.

For additional quality control, methods details and ancillary results, see the Methods Supplement.

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

## RESULTS

To maximize our power for locus discovery we used a single stage design, meta-analyzing all available GWAS summary statistics. Supporting this design, we found strong genetic correlations using PD cases ascertained by clinicians compared to 23andMe self-reported cases (genetic correlation from LDSC ( $r_G$ ) = 0.85, SE = 0.06) and UKB proxy cases ( $r_G$  = 0.84, SE = 0.134).

We identified a total of 90 independent genome-wide significant association signals through our analyses of 37,688 cases, 18,618 UKB proxy-cases and 1,417,791 controls at 7,784,415 SNPs (Figure 2, Table 1, Supplementary Appendices, Table S1, Table S2). Of these, 38 signals are new and more than 1MB from loci described previously (1) (Table S3).

We detected 10 loci containing more than one independent risk signal (22 risk SNPs in total across these loci), of which nine had been identified by previous GWAS, including multi-signal loci in the vicinity of *GBA*, *NUCKS1/RAB29*, *GAK/TMEM175*, *SNCA* and *LRRK2*. The novel multi-signal locus comprised independent risk variants rs2269906 (*UBTF/GRN*) and rs850738 (*FAM171A2*). Detailed summary statistics on all nominated loci can be found in Table S2, including variants filtered out during additional quality control.

To quantify how much of the genetic liability we have explained and what direction to take with future PD GWAS we generated updated heritability estimates and PRS. Using LDSC on a meta-analysis of all 11 clinically-ascertained datasets from our GWAS and estimated the liability-scale heritability of PD as 0.22 (95% CI 0.18 – 0.26), only slightly lower than a previous estimate derived using GCTA (0.27, 95% CI 0.17 – 0.38) (2,16,30). LDSC is known to be more conservative than GCTA, however, our LDSC heritability estimate does fall within the 95% confidence interval of the GCTA estimate.

To determine the proportion of SNP-based heritability explained by our PD GWAS results using PRS, we used a two-stage design, with variant selection and training in the NeuroX-dbGaP dataset (5,851 cases and 5,866 controls) and then validation in the Harvard Biomarker Study (HBS, 527 cases and 472 controls). Using equations from Wray *et al.* 2010 and our current heritability estimates, the 88 variant PRS explained a minimum 16% of the genetic liability of PD assuming a global prevalence of 0.5% (2,31). The 1805 variant PRS explained roughly 26% of PD heritability. In a high-risk population with a prevalence of 2%, the 1805 variant PRS explained a maximum 36% of PD heritable risk (2,31) (Table S4).

We then attempted to quantify strata of risk in our more inclusive PRS. Compared to individuals with PRS values in the lowest quartile, the PD odds ratio for individuals with PRS values in the highest quartile was 3.74 (95% CI = 3.35 – 4.18) in the NeuroX-dbGaP cohort and 6.25 (95% CI = 4.26 – 9.28) in the HBS cohort (Table 2, Figure 3, Figure S1).

Variants in the range of  $5E-08 < P < 1.35E-03$  (used in the 1805 variant PRS) were rarer and had smaller effect estimates than variants reaching genome-wide significance. These sub-significant variants had a median minor allele frequency of 21.3% and a median effect estimate (absolute value of the log odds ratio of the SNP parameter from regression) of 0.047. Genome-wide significant risk variants were more common with a median minor allele frequency of 25.1%, and had a median effect estimate of 0.081. Here we assume that the lower minor allele frequencies and smaller effect size estimates are typical and representative of variants contributing to our more inclusive PRS and represent future GWAS hits. We performed power calculations to forecast the number of additional PD cases needed to achieve genome-wide significance at 80% power for a variant with a minor allele frequency of 21.3% and an effect estimate of 0.047 (32). Assuming that future data is well-harmonized with current data and that disease prevalence is 0.5%, we estimated that we would need a total of ~99K cases, ~2.3 times more than this work for these to reach genome-wide significance. These variants already contribute towards the current increases in AUC when considering the 1805 variant PRS outperforms the 88 variant PRS. Expanding future studies to this size will invariably identify new loci and improve the AUC for a genetic predictor in PD (maximum potential AUC estimated at 85% using the equations from Wray et al. 2010) (31).

There were 305 genes within the 78 GWAS loci. We sought to identify the likely causal gene(s) in each locus using large QTL datasets and summary-data-based Mendelian randomization (Table 3, Table S5, Table S6) (33). This method allows for functional inferences between two datasets to be made in an analogous framework to a randomized controlled trial, treating the genotype as the randomizing factor.

Of the 305 genes under linkage disequilibrium (LD) peaks around our risk variants of interest, 237 were possibly associated with at least one QTL in public reference datasets and were therefore testable via SMR (Methods Supplement, Table S6). The expression or methylation of 151 of these 237 genes (63.7%) was significantly associated with a possible causal change in PD risk.

Of the 90 PD GWAS risk variants, 70 were in loci containing at least one of these putatively causal genes after multiple test correction (Table 3). For 53 out of these 70 PD GWAS hits (75.7%), the gene nearest to the most significant SNP was a putatively causal gene (Table S2). Most loci tested contained multiple putatively causal genes. Interestingly, the nearest putatively causal gene to the rs850738/*FAM171A2* GWAS risk signal is *GRN*, a gene known to be associated with frontotemporal dementia (FTD) (34). Mutations in *GRN* have also been shown to be connected with another lysosomal storage disorder, neuronal ceroid lipofuscinosis (35).



As an orthogonal approach for nominating genes under GWAS peaks we carried out rare coding variant burden analyses. We performed kernel-based burden tests on the 113 genes out of the 305 under our GWAS peaks that contained two or more rare coding variants (MAF < 5% or MAF < 1%). After Bonferroni correction for 113 genes, we identified 7 significant genes: *LRRK2*, *GBA*, *CATSPER3* (rs11950533/*C5orf24* locus), *LAMB2* (rs12497850/*IP6K2* locus), *LOC442028* (rs2042477/*KCNIP3* locus), *NFKB2* (rs10748818/*GBF1* locus), and *SCARB2* (rs6825004 locus). These results suggest that some of the risk associated with these loci may be due to rare coding variants or that these are pleomorphic risk loci. The *LRRK2* and *NFKB2* associations at MAF < 1% remained significant after correcting for all ~20,000 genes in the human genome ( $P = 2.15E-10$  and  $P = 4.02E-07$ , Table S7, Table S5).

We tested whether genes of interest were enriched in 10,651 biological pathways (from gene ontology annotations) using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) (22,36). We found 10 significantly enriched pathways (FDR-adjusted  $P < 0.05$ , Table S8), including four related to vacuolar function and three related to known drug targets (calcium transporters: *ikedamir1\_targets\_dn* and *ikedamir30\_targets\_up*, kinase signaling: *kimpten\_targets\_dn*). At least three candidate genes within novel loci are involved in lysosomal storage disorders (*GUSB*, *GRN*, and *NEU1*), a pathway of keen interest in PD (37). Our GWAS results also include candidate genes *VAMP4* and *NOD2* from the endocytic pathway (38).

To determine the tissues and cell types most relevant to PD etiology using FUMA (22,36) we tested whether the genes highlighted by our PD GWAS were enriched for expression in 53 tissues from across the body. We found 13 significant tissues, all of which were brain-derived (Figure S2A), in contrast to what has been seen in Alzheimer's disease which shows a strong bias towards blood, spleen, lungs and microglial enrichments (39). To further disentangle the enrichment in brain tissues, we tested whether our PD GWAS genes were enriched for expression in 88 brain cell types using single cell RNA sequencing reference data from mouse brains (<http://dropviz.org>) (40). After FDR correction we found seven significant brain cell types, all of which were neuronal (Figure S2B). The strongest enrichment was for neurons in the substantia nigra (SN) at  $P = 1.0E-06$ , with additional significant results at  $P < 5.0E-4$  for the globus pallidus (GP), thalamus (TH), posterior cortex (PC), frontal cortex (FC), hippocampus (HC) and entopeduncular nucleus (ENT).

Next, we used cross-trait genetic correlation and MR to identify possible PD biomarkers and risk factors by comparing with 757 other GWAS datasets curated by LD hub (41). We found four significant genetic correlations (FDR-adjusted  $P < 0.05$ , Table S10) including positive correlations with intracranial volume and putamen volume (42), and negative correlations with current tobacco use and "academic qualifications: National Vocational Qualifications (NVQ) or Higher National Diploma (HND) or Higher National Certificate (HNC) or equivalent" (43). The negative association with one's academic qualifications suggests that individuals without a college education may be at less risk of PD. The correlation between PD and smoking status may not be independent from the correlation between PD and education as smoking status and years of education were significantly correlated (44).



We used MR to assess whether there was evidence of a causal relationship between PD and five phenotypes related to academic qualification, smoking, and brain volumes described above (Figure S4). Cognitive performance had a large, significant causal effect on PD risk (MR effect = 0.213, SE = 0.041, Bonferroni-adjusted P = 8.00E-07), while PD risk did not have a significant causal effect on cognitive performance (Bonferroni-adjusted P = 0.125). Educational attainment also had a significant causal effect on PD risk (MR effect = 0.162, SE = 0.040, Bonferroni-adjusted P = 2.06E-04), but PD risk also had a weak but significant causal effect on educational attainment (MR effect = 0.007, SE = 0.002, Bonferroni-adjusted P = 7.45E-3). There was no significant causal relationship between PD and current smoking status (forward analysis: MR effect = -0.069, SE = 0.031, Bonferroni-adjusted P = 0.125; reverse analysis: MR effect = 0.004, SE = 0.010, Bonferroni-adjusted P = 1). Smoking initiation (the act of ever starting smoking) did not have a causal effect on PD risk (MR effect = -0.063, SE = 0.034, Bonferroni-adjusted P = 0.315), whereas PD had a small, but significantly positive causal effect on smoking initiation (MR effect = 0.027, SE = 0.006, Bonferroni-adjusted P = 1.62E-05). Intracranial volume could not be tested because its GWAS did not contain any genome-wide significant risk variants. There was no significant causal relationship between PD and putamen volume (P > 0.05 in both the forward and reverse directions).

## DISCUSSION

Our work marks a significant step forward in our understanding of the genetic architecture of PD and provides a genetic reference set for the broader research community. We identified 90 independent common genetic risk factors for PD, nearly doubling the number of known PD risk variants. We re-evaluated the cumulative contribution of genetic risk variants, both genome-wide significant and not-yet discovered, in order to refine our estimates of heritable PD risk. We also nominated likely genes at each locus for further follow-up using QTL analyses and rare variant burden analyses. Our work has highlighted the pathways, tissues, and cell types involved in PD etiology. Finally, we identified intracranial and putaminal volume as potential future PD biomarkers, and cognitive performance as a PD risk factor. Altogether, the data presented here has significantly expanded the resources available for future investigations into potential PD interventions.

We were able to explain 16%–36% of PD heritability, the range being directly related to prevalence estimates varying (0.5% to 2%). Power estimates suggest that expansions of case numbers to 99K cases will continue to reveal additional insights into PD genetics. While these risk variants will have relatively small effects and/or be quite rare, they will help to further expand our knowledge of the genes and pathways that drive PD risk.

Population-wide screening for individuals who are likely to develop PD is currently not feasible using our 1805 variant PRS alone. There would be roughly 14 false positives per true positive assuming a prevalence of 0.5%. While large-scale genome sequencing and non-linear machine learning methods will likely improve these predictive models, we have previously shown that we will need to incorporate other data sources (*e.g.* smell tests, family history, age, sex) in order to generate algorithms that have more possible value in population-wide screening (4).

Evaluating these results in the larger context of pathway, tissue, and cellular functionality revealed that genes near PD risk variants showed enrichment for expression in the brain, contrasting with previous work in Alzheimer's disease. Strikingly, we showed that the expression enrichment of genes at PD loci occurred exclusively in neuronal cell types. We also found that PD genes were enriched in chemical signaling pathways and pathways involving the response to a stressor. We believe that this contrast, in which the pathway enrichment analyses suggest at least some immune component to PD and the expression enrichment analysis does not suggest any significant immune related tissue component should be viewed with a critical eye. In particular, the marginal P values of most immune related pathways in our recent analyses after multiple test correction reinforce this moderate view. These observations may be informative for disease modeling efforts, highlighting the importance of disease modeling in neurons and possibly incorporating a cellular stress component. This information can help inform and focus stem cell derived therapeutic development efforts that are currently underway.

We found four phenotypes that were genetically correlated with PD. Putamen and intracranial volumes may prove to be valuable in future PD biomarker studies. Our bi-directional GSMR results suggest a complex etiological connection between smoking initiation and PD that will require further follow-up. One of the implications of this work is that PD trials of nicotine or other smoking-related compound(s) may be less likely to succeed. The strong causal effect of cognitive performance on PD is supported by observational studies (45).

While this study marks major progress in assessing genetic risk factors for PD, there remains a great deal to be done. No defined external validation dataset was used, which may be seen as a limitation. Also, external replication of the novel associations we present will be difficult simply due to the sample sizes needed. Simulations have suggested that without replication variants with P values between  $5E-08$  and  $5E-9$  should be interpreted with greater caution (46,47). We found 16 risk variants in this range, including two known variants near *WNT3* (proximal to the *MAPT* locus) and *BIN3*. To a degree, the fact that we filtered our variants with a secondary random-effects meta-analysis may make our 90 PD GWAS hits somewhat more robust due to the conservative nature of random-effects.

This study focused on PD risk in individuals of European ancestry. Adding datasets from non-European populations would be helpful to further improve our granularity in association testing and ability to fine-map loci through integration of more variable LD signatures while also evaluating population specific associations. Also, risk predictions may not generalize across populations in some cases and ancestry specific PRS should be investigated. Additionally, large ancestry-specific PD LD reference panels, such as those for Ashkenazi Jewish patients, will help us further unravel the genetic architecture of loci such as *GBA* and *LRRK2*. This may be particularly crucial at these loci where LD patterns may be variable within European populations, accentuating the possible influence of LD reference series on conditional analyses in some cases (48). Finally, our work utilized state-of-the-art QTL datasets to nominate candidate genes, but many QTL associations are hampered by both small sample size and low *cis*-SNP density. Larger QTL studies and

PD-specific network data from large scale cellular screens would allow us to build a more robust functional inference framework.

As the field moves forward there are some critical next steps that should be prioritized. First, allowing researchers to share participant-level data in a secure environment would facilitate inclusiveness and uniformity in analyses while maintaining the confidentiality of study participants. Our work suggests that GWASes of increasing size will continue to provide useful biological insights into PD. In addition to studies of the genetics of PD risk, studies of disease onset, progression, and subtype will be important and will require large series of well-characterized patients(49). We also believe that work across diverse populations is important, not only to be able to best serve these populations but also to aid in fine mapping of loci. Notably, the use of genome sequencing technologies could further improve discovery by capturing rare variants and structural variants, but with the caveat that very large sample sizes will be required. While there is still much left to do, we believe that our current work represents a significant step forward and that the results and data will serve as a foundational resource for the community to pursue this next phase of PD research.

## DATA ACCESS

GWAS summary statistics for 23andMe datasets (post-Chang and data included in Chang et al. 2017 and Nalls et al. 2014) will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit [research.23andme.com/collaborate/#publication](https://research.23andme.com/collaborate/#publication) for more information and to apply to access the data. An immediately accessible version of the summary statistics is available [here](#) excluding Nalls et al. 2014, 23andMe post-Chang et al. 2017 and Web-Based Study of Parkinson's Disease (PDWBS) but including all analyzed SNPs. After applying with 23andMe, the full summary statistics including all analyzed SNPs and samples in this GWAS meta-analysis will be accessible to the approved researcher(s). Underlying participant level IPDGC data is available to potential collaborators, please contact [ipdgc.contact@gmail.com](mailto:ipdgc.contact@gmail.com).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Authors

Mike A. Nalls, PhD<sup>1,2,CA,\*</sup>, Cornelis Blauwendraat, PhD<sup>1,\*</sup>, Costanza L. Valleria, MS<sup>3,4,\*</sup>, Karl Heilbron, PhD<sup>5,\*</sup>, Sara Bandres-Ciga, PhD<sup>1,\*</sup>, Diana Chang, PhD<sup>6,\*</sup>, Manuela Tan, MS<sup>7</sup>, Demis A. Kia, BS<sup>7</sup>, Alastair J. Noyce, MD, PhD<sup>7,8</sup>, Angli Xue, BS<sup>3,4</sup>, Jose Bras, PhD<sup>9,10</sup>, Emily Young, PhD<sup>11</sup>, Rainer von Coelln, MD<sup>12</sup>, Javier Simón-Sánchez, PhD<sup>13,14</sup>, Claudia Schulte, PhD<sup>13,14</sup>, Manu Sharma, PhD<sup>15</sup>, Lynne Krohn, MS<sup>16,17</sup>, Lasse Pihlstrom, MD, PhD<sup>18</sup>, Ari Siitonen, PhD<sup>19,20</sup>, Hirotaka Iwaki, MD, PhD<sup>1,2,21</sup>, Hampton Leonard, MS<sup>1,2</sup>, Faraz Faghri, PhD<sup>1,22</sup>, J. Raphael Gibbs, PhD<sup>1</sup>, Dena G. Hernandez, PhD<sup>1</sup>, Sonja W. Scholz, MD, PhD<sup>23,24</sup>, Juan A. Botia, PhD<sup>7,25</sup>, Maria Martinez, PhD<sup>26</sup>, Jean-Christophe Corvol, PhD<sup>27</sup>, Suzanne Lesage,

PhD<sup>27</sup>, Joseph Jankovic, MD<sup>11</sup>, Lisa M. Shulman, MD<sup>11</sup>, Margaret Sutherland, PhD<sup>28</sup>, Pentti Tienari, MD, PhD<sup>29,30</sup>, Kari Majamaa, MD<sup>19,20</sup>, Mathias Toft, MD, PhD<sup>18,31</sup>, Ole A. Andreassen, MD<sup>32,33</sup>, Tushar Bangale, PhD<sup>6</sup>, Alexis Brice, MD, PhD<sup>27</sup>, Jian Yang, PhD<sup>3,4</sup>, Ziv Gan-Or, MD, PhD<sup>16,17,34</sup>, Thomas Gasser, MD<sup>13,14</sup>, Peter Heutink, PhD<sup>13,14</sup>, Joshua M Shulman, MD, PhD<sup>11,35,36</sup>, Nicolas Wood, MD<sup>7</sup>, David A. Hinds, PhD<sup>5</sup>, John A. Hardy, PhD<sup>7</sup>, Huw R Morris, MD, PhD<sup>37,38</sup>, Jacob Gratten, PhD<sup>3,4</sup>, Peter M. Visscher, PhD<sup>3,4</sup>, Robert R. Graham, PhD<sup>6</sup>, Andrew B. Singleton, PhD<sup>1</sup> **23andMe Research Team, System Genomics of Parkinson's Disease (SGPD) Consortium and the International Parkinson's Disease Genomics Consortium**

## Affiliations

<sup>1</sup>Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892 USA

<sup>2</sup>Data Tecnica International, Glen Echo, MD, 20812 USA

<sup>3</sup>Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072 Australia

<sup>4</sup>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072 Australia

<sup>5</sup>23andMe, Inc., Mountain View, California 94041 USA

<sup>6</sup>Department of Human Genetics, Genentech, South San Francisco, 94080, CA, USA

<sup>7</sup>Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

<sup>8</sup>Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK

<sup>9</sup>Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA

<sup>10</sup>Department of Neurodegenerative Diseases, UCL Institute of Neurology, University College London, London, UK

<sup>11</sup>Department of Neurology, Baylor College of Medicine, Houston, USA

<sup>12</sup>Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA

<sup>13</sup>Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

<sup>14</sup>German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

<sup>15</sup>Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Germany

<sup>16</sup>Department of Human Genetics, McGill University, Montreal, Quebec, Canada

- <sup>17</sup>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
- <sup>18</sup>Department of Neurology, Oslo University Hospital, Oslo, Norway
- <sup>19</sup>Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland
- <sup>20</sup>Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland
- <sup>21</sup>The Michael J. Fox Foundation, New York, New York, 10036 USA
- <sup>22</sup>Department of Computer Science, University of Illinois Urbana-Champaign, Champaign, IL, 61820, USA
- <sup>23</sup>Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
- <sup>24</sup>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD 21287, USA
- <sup>25</sup>Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, Spain
- <sup>26</sup>INSERM UMR 1220; and Paul Sabatier University, Toulouse, France
- <sup>27</sup>INSERM U1127, CNRS UMR 7225, Sorbonne Université UMR S1127, APHP, Institut du Cerveau et de la Moelle épinière, ICM, Paris F-75013, France
- <sup>28</sup>National Institute on Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892 USA
- <sup>29</sup>Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland
- <sup>30</sup>Helsinki University Hospital, Helsinki, Finland
- <sup>31</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- <sup>32</sup>Jebsen Centre for Psychosis Research, University of Oslo, Oslo, Norway
- <sup>33</sup>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- <sup>34</sup>Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada
- <sup>35</sup>Departments of Molecular & Human Genetics and Neuroscience, Baylor College of Medicine, Houston, USA
- <sup>36</sup>Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston
- <sup>37</sup>Department of Clinical Neuroscience, UCL Institute of Neurology, London UK
- <sup>38</sup>UCL Movement Disorders Centre, UCL Institute of Neurology, London, UK

## ACKNOWLEDGEMENTS

See supplemental materials (Text S2).

## Disclosures and conflicts of interest

Dr. Nalls reports that this work was carried out under a consulting contract with NIH, he also consults for Lysosomal Therapeutics Inc, Neuron23 Inc and Illumina Inc. Dr. Heilbron reports other support from 23andMe, during the conduct of the study outside the submitted work. Dr. Chang reports other support from Genentech outside the submitted work. Ms. Tan reports grants from Parkinson's UK during the conduct of the study. Dr. Noyce reports grants from Parkinson's UK, grants from Virginia Kieley benefaction, grants and non-financial support from GE Healthcare, personal fees from Profile, Bial and Britannia, outside the submitted work. Dr. von Coelln reports grants from American Brain Foundation, grants from Michael and Eugenia Brin Foundation, during the conduct of the study. Dr. Pihlstrøm reports grants from Southeastern Regional Health Authority, Norway, during the conduct of the study. Dr. Siitonen reports grants from Sigrid Juselius Foundation, during the conduct of the study. Dr. Scholz is a scientific advisory council member for the Lewy Body Dementia Association. Dr. Corvol reports grants from French Ministry of Health, during the conduct of the study; grants from Sanofi, personal fees from Ever Pharma, personal fees from Denali, personal fees from Biogen, personal fees from Air Liquide, personal fees from BrainEver, personal fees from Theranexus, outside the submitted work. Dr. L Shulman reports grants from NIH, outside the submitted work. Dr. Tienari reports no conflicts of interest. In addition, Dr. Tienari has a patent c9orf72 in the diagnosis and treatment of neurodegenerative disease pending. Dr. Toft reports grants from Research Council of Norway, grants from Regional Health Authority South-Eastern Norway, grants from Michael J. Fox Foundation, personal fees from Roche, outside the submitted work. Dr. Andreassen reports grants from Research Council of Norway, grants from KG Jebsen Stiftelsen, during the conduct of the study; personal fees from Lundbeck, outside the submitted work; In addition, Dr. Andreassen has a patent PCT/US2014/011014 pending. Dr. Bhangale reports other from Genentech, outside the submitted work. Dr. BRICE reports grants from France Parkinson + FRC, grants from ANR - EPIG - Agence nationale de recherche, grants from ANR - JPND - Agence nationale de recherche, grants from RDS (Roger de Spoelberch Foundation), grants from France Alzheimer, grants from ENP -Ecole des neurosciences Paris, grants from Institut de France, grants from CHU de Nimes, grants from ERA NET, grants from ANR - EPIG, grants from APHP, outside the submitted work. Dr. Gan-Or reports personal fees from Lysosomal Therapeutics Inc, personal fees from Idorsia, personal fees from Inception Sciences, personal fees from Denali, personal fees from Prevail Therapeutics, outside the submitted work. Dr. Gasser reports grants from The Michael J Fox Foundation for Parkinson's Research, personal fees from UCB Pharma, other from "Joint Programming for Neurodegenerative Diseases" program, funded by the European Commission, personal fees from Novartis, personal fees from Teva, personal fees from MedUpdate, outside the submitted work; In addition, Dr. Gasser has a patent Patent Number: EP1802749 (A2) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders issued. Dr. Heutink is a consultant for NEURON23, inc. Dr. J Shulman reports grants from Burroughs Wellcome Fund during the conduct of the study; grants from National Institutes of Health and personal fees from Helis Medical Foundation, outside the submitted work. Dr. Hinds reports other from 23andMe, Inc., outside the submitted work. Dr. Morris reports grants from Parkinson's UK, grants from Medical Research Council, grants from Cure Parkinson's Trust, during the conduct of the study; grants from PSP Association, grants from CBD Solutions, personal fees from Teva, personal fees from Boehringer Ingelheim, personal fees from GSK, grants from Drake Foundation, personal fees from Biogen, personal fees from UCB, personal fees from Biohaven, outside the submitted work. Dr. Graham reports other from Genentech, during the conduct of the study; other from Genentech, outside the submitted work.

## WORKS CITED

1. Chang D, Nalls MA, Hallgrímsdóttir IB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet* 2017;10(10):1511–6. [PubMed: 28892059]
2. Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sánchez J, et al. Using genome-wide complex trait analysis to quantify "missing heritability" in Parkinson's disease. *Hum Mol Genet* 2012;21(22):4996–5009. [PubMed: 22892372]
3. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin U-M, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*. 2011;377(9766):641–9. [PubMed: 21292315]
4. Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. *Lancet Neurol* 2015;14(10):1002–9. [PubMed: 26271532]
5. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology*. 2007;68(5):384–6. [PubMed: 17082464]



6. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. *Science*. 1996;115(274):1197–9. [PubMed: 8895469]
7. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. *Science*. 2003;302(5646):841. [PubMed: 14593171]
8. Fung H-C, Scholz S, Matarin M, Simón-Sánchez J, Hernandez D, Britton A, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurol* 2006;11(11):911–6. [PubMed: 17052657]
9. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet* 2014;46(9):989–93. [PubMed: 25064009]
10. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190–1. [PubMed: 20616382]
11. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 2012;44(4):369–75, S1–3. [PubMed: 22426310]
12. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. *Bioinformatics*. 2014;31(9):1466–8. [PubMed: 25550326]
13. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin U-M, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*. 2011;377(9766):641–9. [PubMed: 21292315]
14. International Parkinson's Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-analysis identifies several new loci for Parkinson's disease. *PLoS Genet* 2011;7(6):e1002142. [PubMed: 21738488]
15. Nalls MA, Escott-Price V, Williams NM, Lubbe S, Keller MF, Morris HR, et al. Genetic risk and age in Parkinson's disease: Continuum not stratum. *Mov Disord* 2015;30(6):850–4. [PubMed: 25778492]
16. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* 2015;47(3):291–5. [PubMed: 25642630]
17. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2016;48(6):580–5. [PubMed: 23715323]
18. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. *Nat Commun* 2018;9(1):2282. [PubMed: 29891976]
19. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet* 2016;48(5):481–7. [PubMed: 27019110]
20. Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, et al. Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nat Commun* 2018;9(1):918. [PubMed: 29500431]
21. Vösa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis [Internet]. *bioRxiv* 2018 [cited 2018 Oct 25]. p. 447367. Available from: <https://www.biorxiv.org/content/early/2018/10/19/447367.abstract>
22. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 2017;8(1):1826. [PubMed: 29184056]
23. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. *Nat Protoc* 2015;10(10):1556–66. [PubMed: 26379229]



24. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. *Am J Hum Genet* 2012;91(2):224–37. [PubMed: 22863193]
25. LD Hub [Internet]. [cited 2018 Jun 20]. Available from: <http://ldsc.broadinstitute.org/ldhub/>
26. Prins BP, Abbasi A, Wong A, Vaez A, Nolte I, Franceschini N, et al. Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study. *PLoS Med* 2016;13(6):e1001976. [PubMed: 27327646]
27. Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, et al. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. *Am J Hum Genet* 2017;100(1):40–50. [PubMed: 27989323]
28. Lee JJ, Wedow R, Okbay A, Kong E, Maghziyan O, Zacher M, et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* [Internet]. 2018;723; Available from: 10.1038/s41588-018-0147-3
29. Elliott LT, Sharp K, Alfaro-Almagro F, Shi S, Miller KL, Douaud G, et al. Genome-wide association studies of brain imaging phenotypes in UK Biobank. *Nature*. 2018;562(7726):210–6. [PubMed: 30305740]
30. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011;88(1):76–82. [PubMed: 21167468]
31. Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. *PLoS Genet* 2010;6(2):e1000864. [PubMed: 20195508]
32. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet* 2006;38(2):209–13. [PubMed: 16415888]
33. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet* 2016;48(5):481–7. [PubMed: 27019110]
34. Cruts M, Gijselink I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature*. 2006;442(7105):920–4. [PubMed: 16862115]
35. Smith KR et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. - PubMed - NCBI [Internet]. [cited 2019 Jan 10]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/22608501>
36. Wang J, Vasaiakar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res* 2017;45(W1):W130–7. [PubMed: 28472511]
37. Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. *Brain*. 2017;140(12):3191–203. [PubMed: 29140481]
38. Bandres-Ciga S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, Vitale D, Blauwendraat C, et al. The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. *Mov Disord* 2014;34(4):460–8. [PubMed: 30675927]
39. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet* [Internet]. 2019; Available from: 10.1038/s41588-018-0311-9
40. Saunders A et al. Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. - PubMed - NCBI [Internet]. [cited 2018 Oct 31]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/30096299>
41. LD Hub [Internet]. [cited 2018 Jun 26]. Available from: <http://ldsc.broadinstitute.org>
42. Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivieres S, Jahanshad N, et al. Common genetic variants influence human subcortical brain structures. *Nature*. 2015;520(7546):224–9. [PubMed: 25607358]

43. Rapid GWAS of thousands of phenotypes for 337,000 samples in the UK Biobank [Internet]. Neale lab. [cited 2018 Jun 24]. Available from: <http://www.nealelab.is/blog/2017/7/19/rapid-gwas-of-thousands-of-phenotypes-for-337000-samples-in-the-uk-biobank>
44. Bulik-Sullivan B, ReproGen Consortium, Finucane HK, Anttila V, Gusev A, Day FR, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet.* 2015;47(11):1236–41. [PubMed: 26414676]
45. Valdés EG, Andel R, Sieurin J, Feldman AL, Edwards JD, Långström N, et al. Occupational complexity and risk of Parkinson’s disease. *PLoS One.* 2014;9(9):e106676. [PubMed: 25198429]
46. Wu Y, Zheng Z, Visscher PM, Yang J. Quantifying the mapping precision of genome-wide association studies using whole-genome sequencing data. *Genome Biol* 2017;18(1):86. [PubMed: 28506277]
47. Pulit SL, de With SAJ, de Bakker PIW. Resetting the bar: Statistical significance in whole-genome sequencing-based association studies of global populations. *Genet Epidemiol* 2017;41(2):145–51. [PubMed: 27990689]
48. Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. *PLoS Genet* 2018;14(5):e1007329. [PubMed: 29795570]
49. Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, et al. Genome-wide association study of Parkinson’s disease progression biomarkers in 12 longitudinal patients’ cohorts [Internet]. *bioRxiv.* 2019 [cited 2019 Apr 25]. p. 585836. Available from: 10.1101/585836v1.abstract

## RESEARCH IN CONTEXT

### Evidence before this study

Previous studies such as Chang et al. 2017 and its predecessors have utilized GWAS methods to discover 42 independent risk loci associated with PD (1). Some of these loci harboring common risk variants also include rare variants implicated in familial PD risk such as *SNCA*, *LRRK2* or *GBA*. Earlier studies like Keller et al. 2012 have attempted to quantify how much heritable risk is captured by common variation that can be easily imputed using commercial genotyping arrays and estimate the amount of risk explained by GWAS (2). As far back as Nalls et al. 2011, GWAS studies of PD have integrated expression and methylation datasets to evaluate possible candidate genes for follow-up at PD loci (3). Many epidemiological and observational studies have attempted to assess risk of PD and various exposures like smoking, caffeine or occupational hazards, with a mixed track record of success at validating putative associations.

### Added value of this study

The primary deliverable of this study was increasing the count of independent common genetic risk factors for PD to 90. We added 38 novel risk variants not identified as genome-wide significant in previous reports. We refined heritability estimates and genetic risk predictions suggesting that common genetic variants account for approximately 22% of PD risk on the liability scale, with a range of 16–36% of that risk being explained by GWAS loci in this study. These updated risk predictions also suggested that polygenic risk scoring can be used to achieve an area under the curve of near 70%, although this prediction uses many more variants than just the 90 independent risk factors identified in this report. Of the 90 risk variants we have characterized here, we have nominated at least one possible candidate gene for follow-up functional studies in 70 of these genomic regions by mining recently available expression and methylation reference datasets on a scale not possible just a few years ago. We have additionally mined single cell RNA sequencing data from mice to identify tissue-specific signatures of enrichment relating to PD genetic risk, showing a major focus on neuronal cell types. We also utilized the massive amount of publicly available GWAS results to survey genetic correlations between PD and other phenotypes showing significant correlations with smoking, education and brain morphology. Subsequent analyses using Mendelian randomization (MR) methods showed that there are likely causal links between increased cognitive performance and PD risk on a genetic level.

### Implications of all available evidence

First and foremost, this study increased the scope of our knowledge of PD genetics by adding 38 novel risk factors, directly broadening our knowledge base of disease etiology. Using updated heritability estimates and risk predictions, we took preliminary steps down the long path to early detection. In future studies, combining genetic and clinico-demographic risk factors may lead to earlier detection and refined diagnostics, which may help improve clinical trials (4). The generation of copious amounts of public summary statistics created by this effort relating to both the GWAS and subsequent analyses of gene expression and methylation patterns may be of use to investigators


planning follow-up functional studies in stem cells or other cellular screens, allowing them to prioritize targets more efficiently using our data as additional evidence. We hope our findings may have some downstream clinical impact in the future such as improved patient stratification for clinical trials and genetically informed drug targets.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Figure 1: Workflow and rationale summary.**


This figure describes study design and rationale behind the analyses included in this report.




**Figure 2: Manhattan plot.**

The nearest gene to each of the 90 significant variants are labeled in green for previously-identified loci and in blue for novel loci.  $-\log_{10} P$  values were capped at 40. Variant points are color coded red and orange, with orange representing significant variants at  $P$  5E-08 and 5E-9 and red representing significant variants at  $P < 5E-9$ . The X axis represents the base pair position of variants from smallest to largest per chromosome (1–22).

A







**Figure 3: Predictive model details.**

A. The odds ratio of developing PD for each quartile of polygenic risk score (PRS) compared to the lowest quartile of genetic risk. B. PRS receiver-operator curves for the more inclusive 1805 variant PRS in the validation dataset as well as in the corresponding training dataset that was used for PRS thresholding and SNP selection.

**Table 1.**

Novel loci associated with Parkinson's disease.

SNP	CHR	BP	Nearest Gene	Effect allele	Other allele	Effect allele frequency	OR	Low 95% CI	High 95% CI	Beta	SE	P, fixed-effects	P, COJO	P, conditional	P, random-effects	I <sup>2</sup> , %
rs6658353	1	161469054	FCGR2A	c	g	0.501	1.07	1.05	1.09	0.065	0.009	6.10E-12	4.69E12	1.38E-05	3.71E-05	40.2
rs11578699	1	171719769	VAMP4	t	c	0.195	0.93	0.91	0.95	-0.070	0.012	4.47E-09	4.45E09	2.63E-03	1.09E-07	5.1
rs76116224	2	18147848	KCNS3	a	t	0.904	1.12	1.08	1.16	0.110	0.019	1.27E-08	1.27E08	3.75E-07	1.27E-08	0
rs2042477	2	96000943	KCNIP3	a	t	0.242	0.94	0.92	0.96	-0.066	0.012	1.38E-08	1.48E08	3.49E-05	1.38E-08	0
rs6808178	3	28705690	LINC00693	t	c	0.379	1.07	1.05	1.09	0.066	0.010	8.09E-12	7.18E12	8.84E-05	8.09E-12	0
rs55961674	3	122196892	KPNA1	t	c	0.172	1.09	1.06	1.12	0.086	0.013	9.98E-12	8.30E12	2.80E-06	9.98E-12	0
rs11707416	3	151108965	MED12L	a	t	0.367	0.94	0.92	0.96	-0.063	0.010	1.13E-10	1.02E10	2.66E-04	1.77E-07	10.9
rs1450522	3	161077630	SPTSSB	a	g	0.674	0.94	0.92	0.96	-0.062	0.010	5.01E-10	4.90E10	3.51E-04	2.27E-05	24.6
rs34025766	4	17968811	LCORL	a	t	0.159	0.92	0.90	0.94	-0.084	0.013	2.87E-10	2.82E10	7.43E-06	2.87E-10	0
rs62333164	4	170583157	CLCN3	a	g	0.326	0.94	0.92	0.96	-0.064	0.010	2.00E-10	1.77E10	5.10E-05	2.17E-05	21.3
rs26431	5	102365794	PAM	c	g	0.703	1.06	1.04	1.09	0.062	0.010	1.57E-09	1.65E09	6.00E-03	2.36E-07	7.9
rs11950533	5	134199105	C5orf24	a	c	0.102	0.91	0.88	0.94	-0.092	0.016	7.16E-09	6.73E09	5.08E-04	2.68E-08	1.9
rs9261484	6	30108683	TRIM40	t	c	0.245	0.94	0.92	0.96	-0.064	0.011	1.62E-08	1.43E08	1.26E-06	1.62E-08	0
rs12528068	6	72487762	RIMS1	t	c	0.284	1.07	1.05	1.09	0.066	0.010	1.63E-10	1.79E10	9.80E-06	1.63E-10	0
rs97368	6	112243291	FYN	a	g	0.805	1.07	1.05	1.10	0.071	0.012	1.84E-09	1.97E09	2.61E-05	1.84E-09	0
rs75859381	6	133210361	RPS12	t	c	0.967	0.80	0.75	0.86	-0.221	0.034	1.04E-10	9.67E11	1.09E-06	1.04E-10	0

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

SNP	CHR	BP	Nearest Gene	Effect allele	Other allele	Effect allele frequency	OR	Low 95% CI	High 95% CI	Beta	SE	P, fixed-effects	P, COJO	P, conditional	P, random-effects	I <sup>2</sup> , %
rs76949143	7	66009851	GS1-124K5.11	a	t	0.051	0.87	0.82	0.91	-0.143	0.025	1.43E-08	1.51E08	5.47E-09	2.04E-06	12.3
rs2086641	8	130901909	FAM49B	t	c	0.723	0.94	0.92	0.96	-0.061	0.011	1.81E-08	1.57E08	6.07E-06	1.81E-08	0
rs6476434	9	34046391	UBAP2	t	c	0.734	0.94	0.92	0.96	-0.062	0.011	6.58E-09	6.56E09	2.74E-04	6.58E-09	0
rs10748818	10	104015279	GBF1	a	g	0.851	0.92	0.90	0.95	-0.079	0.013	1.05E-09	1.23E09	7.47E-06	1.05E-09	0
rs7938782	11	10558777	RNF141	a	g	0.878	1.09	1.06	1.12	0.087	0.015	2.12E-09	1.97E09	2.17E-07	2.12E-09	0
rs7134559	12	46419086	SCAF11	t	c	0.404	0.95	0.93	0.97	-0.054	0.010	3.96E-08	3.80E08	1.69E-02	1.84E-05	25.2
rs11610045	12	133063768	FBRSL1	a	g	0.490	1.06	1.04	1.08	0.060	0.009	1.77E-10	1.62E10	3.57E-05	8.79E-07	19.5
rs9568188	13	49927732	CAB39L	t	c	0.740	1.06	1.04	1.09	0.062	0.011	1.15E-08	1.11E08	4.29E-06	2.46E-04	21.4
rs4771268	13	97865021	MBNL2	t	c	0.230	1.07	1.05	1.09	0.068	0.011	1.45E-09	1.67E09	1.41E-04	1.45E-09	0
rs12147950	14	37989270	MIPOL1	t	c	0.438	0.95	0.93	0.97	-0.053	0.010	3.54E-08	3.58E08	1.06E-03	3.54E-08	0
rs3742785	14	75373034	RPS6KL1	a	c	0.787	1.07	1.05	1.10	0.071	0.012	1.92E-09	2.08E09	2.22E-06	8.18E-06	24.8
rs2904880	16	28944396	CD19	c	g	0.309	0.94	0.92	0.96	-0.065	0.011	7.87E-10	8.68E10	1.39E-05	7.87E-10	0
rs6500328	16	50736656	NOD2	a	g	0.599	1.06	1.04	1.08	0.059	0.010	1.82E-09	1.53E09	1.43E-03	1.82E-09	0
rs12600861	17	7355621	CHRN1	a	c	0.648	0.95	0.93	0.96	-0.057	0.010	1.01E-08	1.15E08	5.10E-03	1.01E-08	0
rs2269906	17	42294337	UBTF	a	c	0.653	1.07	1.04	1.09	0.063	0.010	6.24E-10	8.63E09	1.17E-05	6.24E-10	0
rs850738	17	42434630	FAM171A2	a	g	0.606	0.93	0.91	0.95	-0.071	0.011	1.29E-11	3.55E10	4.18E-04	2.17E-07	17
rs61169879	17	59917366	BRIP1	t	c	0.164	1.09	1.06	1.11	0.082	0.013	9.28E-10	9.40E10	9.07E-07	6.21E-06	16.4
rs666463	17	76425480	DNAH17	a	t	0.833	1.08	1.05	1.11	0.076	0.013	3.20E-09	2.90E09	1.62E-05	4.17E-04	41

SNP	CHR	BP	Nearest Gene	Effect allele	Other allele	Effect allele frequency	OR	Low 95% CI	High 95% CI	Beta	SE	P, fixed-effects	P, COJO	P, conditional	P, random-effects	I <sup>2</sup> , %
rs1941685	18	31304318	ASXL3	t	g	0.498	1.05	1.04	1.07	0.053	0.009	1.69E-08	1.61E08	1.64E-08	1.69E-08	0
rs8087969	18	48683589	MEX3C	t	g	0.550	0.94	0.93	0.96	-0.058	0.010	1.41E-08	1.46E08	1.09E-04	1.41E-08	0
rs77351827	20	6006041	CRLS1	t	c	0.128	1.08	1.05	1.11	0.080	0.014	8.87E-09	7.94E09	1.84E-05	4.38E-07	11.2
rs2248244	21	38852361	DYRK1A	a	g	0.283	1.07	1.05	1.10	0.071	0.011	2.74E-11	2.51E11	6.31E-05	8.78E-06	34.3

Summary statistics for 38 novel genome-wide significant PD variants. Columns include single nucleotide polymorphism ID (SNP), chromosome (CHR), base pair position (BP) based on hg19 build, nearest gene annotation for the variant, effect allele designation and frequency, as well as metrics for the odds ratio (OR), regression coefficient (beta), and standard error of the beta for the SNP from fixed-effects meta-analysis as well as the index of heterogeneity (I<sup>2</sup>). We also include four P values from: fixed-effects meta-analyses, random-effects meta-analyses, standard conditional analyses in 23andMe, and a conditional joint analysis approach (COJO).

**Table 2.**

Summary of genetic predictive model performance.

Study	Max P threshold	pseudo R2 from PRS*	Beta	SE	P	OR, highest quartile PRS	95% CI, highest quartile PRS	N SNPs	N samples	AUC	95% CI (DeLong)	Sensitivity	Specificity	Positive predictive value (PPV)	Negative predictive value (NPV)	Balanced accuracy
Training dataset: IPDGC Neurox	1.35E-03	0.029	0.553	0.022	8.99E-135	3.74	3.35 – 4.18	1809	11,243	0.640	0.630 – 0.650	0.569	0.632	0.591	0.611	0.601
Test dataset: HBS	4.00E-02	0.054	0.709	0.072	8.28E-23	6.25	4.26 – 9.28	1805	999	0.692	0.660 – 0.725	0.628	0.686	0.691	0.623	0.657

These are estimates of performance for predictive models including single study estimates, estimates from meta-analyses across studies, as well as a two stage design. Here the best P value threshold column denotes the filtering value for SNP inclusion to achieve the maximal pseudo (Nagelkerke's) R2. The odds ratio (OR) column is the exponent of the regression coefficient (beta) from logistic regression of the polygenic risk score (PRS) on case status, with the standard error (SE) representing the precision of these estimates. These same metrics are derived across array types and datasets using random-effects meta-analyses. The area under the curve (AUC) is included as the most common metric for predictive model performance. In the table

\* denotes R2 approximation adjusted for an estimated prevalence of 0.5%, equivalent to roughly half of the unadjusted R2 estimates for the PRS. All calculations and reported statistics include only the PRS and no other parameters after adjusting for principal components 1-5, age and sex at variant selection in the NeuroX-dbGaP dataset.

Table 3.

Summary of significant functional inferences from QTL associations via Mendelian randomization for nominated genes of interest.

Gene	Probe	CHR	Probe, BP	Top SNP, BP	Top SNP	N SNPs	QTL reference	Effect	SE	P	Bonferroni adjusted P
VAMP4	ENSG00000117533	1	171,690,343	171,717,417	rs10913587	98	Vösa et al. 2018 - blood expression	-0.272	0.05	5.67E07	1.19E-04
KCNIP3	ENSG00000115041	2	96,007,438	95,989,766	rs3772034	14	Qi et al. 2018 - brain expression	-0.161	0.04	1.12E05	1.15E-03
MAP4K4	ENSG00000071054	2	102,410,880	102,338,377	rs6733355	3	Vösa et al. 2018 - blood expression	1.119	0.24	2.32E06	4.87E-04
TMEM163	ENSG00000152128	2	135,344,950	135,248,544	rs598668	28	Qi et al. 2018 - brain expression	0.074	0.02	3.55E07	3.65E-05
KPNA1	ENSG00000114030	3	122,187,294	122,201,610	rs73190142	110	Vösa et al. 2018 - blood expression	0.310	0.05	1.56E06	3.28E-04
GAK	ENSG00000178950	4	884,612	906,131	rs11248057	1	Qi et al. 2018 - brain expression	0.508	0.10	7.47E07	7.69E-05
CAMK2D	ENSG00000145349	4	114,527,635	114,730,260	rs115671064	146	Vösa et al. 2018 - blood expression	-0.006	0.05	5.74E06	1.21E-03
PAM	ENSG00000145730	5	102,228,247	102,118,633	rs2432162	679	Vösa et al. 2018 - blood expression	-0.031	0.01	2.08E06	4.36E-04
LOC100131289	cg21339923	6	27,636,378	27,636,378	rs78149975	2	Qi et al. 2018 - brain methylation	-0.094	0.02	1.53E06	3.06E-04
TRIM40	cg01641092	6	30,094,300	30,094,315	rs9261443	8	Qi et al. 2018 - brain methylation	0.072	0.01	6.15E06	1.23E-03
HLA-DRB5	cg26036029	6	32,552,443	32,570,311	rs34039593	8	Qi et al. 2018 - brain methylation	-0.153	0.02	7.53E10	1.51E-07
GPNMB	ENSG00000136235	7	23,295,156	23,294,668	rs858274	74	Qi et al. 2018 - brain expression	0.090	0.01	2.73E21	2.81E-19
CTSB	ENSG00000164733	8	11,713,495	11,699,279	rs4631423	33	Qi et al. 2018 - brain expression	-0.150	0.04	4.37E09	4.50E-07
BIN3	ENSG00000147439	8	22,502,296	22,456,517	rs71513892	32	Qi et al. 2018 - brain expression	0.046	0.01	1.43E06	1.48E-04
SH3GL2	ENSG00000107295	9	17,688,103	17,684,784	rs10756899	15	Qi et al. 2018 - brain expression	0.252	0.05	5.83E08	6.00E-06
ITGA8	ENSG00000077943	10	15,659,036	15,548,925	rs7910668	6	Qi et al. 2018 - brain expression	-0.201	0.05	6.13E05	6.32E-03
RNF141	ENSG00000110315	11	10,548,001	10,553,355	rs4910153	120	Vösa et al. 2018 - blood expression	-0.054	0.05	6.25E07	1.31E-04
IGSF9B	cg25790212	11	133,800,774	133,800,477	rs11223626	1	Qi et al. 2018 - brain methylation	-0.172	0.04	3.24E06	6.48E-04
FBRSL1	cg03621470	12	133,137,479	133,138,334	rs10781619	16	Qi et al. 2018 - brain methylation	-0.057	0.01	6.35E05	1.27E-02
CAB39L	ENSG00000102547	13	49,950,524	49,918,175	rs35214871	30	Qi et al. 2018 - brain expression	0.097	0.02	3.51E08	3.62E-06

Gene	Probe	CHR	Probe, BP	Top SNP, BP	Top SNP	N SNPs	QTL reference	Effect	SE	P	Bonferroni adjusted P
GCH1	ENSG00000131979	14	55,339,148	55,348,837	rs3825611	6	Qi et al. 2018 - brain expression	0.113	0.03	2.76E04	2.83E-02
SYT17	ENSG00000103528	16	19,229,472	19,273,354	rs727747	4	Qi et al. 2018 - brain expression	0.177	0.05	1.54E04	1.58E-02
SETD1A	ENSG00000099381	16	30,982,526	30,950,352	rs7206511	34	Vösa et al. 2018 - blood expression	-0.710	0.09	2.75E13	5.77E-11
CHRN1	ENSG00000170175	17	7,354,703	7,373,595	rs60488855	18	Qi et al. 2018 - brain expression	0.115	0.03	1.67E05	1.72E-03
UBTF	ENSG00000108312	17	42,290,697	42,297,631	rs113844752	34	Vösa et al. 2018 - blood expression	-0.466	0.09	5.68E06	1.19E-03
MAPT	ENSG00000186868	17	44,038,724	44,862,347	rs199502	6	Qi et al. 2018 - brain expression	0.265	0.03	7.13E24	7.35E-22
WNT3	ENSG00000108379.5	17	44,875,148	44,908,263	rs9904865	2	GTEX v7 - substantia nigra brain expression	-0.082	0.02	4.01E06	4.81E-05
DNAH17	cg09006072	17	76,425,972	76,427,732	rs589582	3	Qi et al. 2018 - brain methylation	0.100	0.02	2.44E05	4.88E-03
MEX3C	ENSG00000176624	18	48,722,797	48,731,131	rs12458916	40	Vösa et al. 2018 - blood expression	-0.291	0.05	5.28E05	1.11E-02

Multi-SNP eQTL Mendelian randomization results focusing only on the most significant association per nearest gene to the PD risk variant of interest after Bonferroni correction. If a locus was significantly associated with both brain and blood QTLs after multiple test correction, we opted to show the most significant brain tissue derived association here after filtering for possible polygenicity (HEIDI P > 0.01). Effects with significant HEIDI P values may indicate a possible effect complicated by LD and are less likely to be a true causal association. All tested QTL summary statistics can be found in Supplementary Table S6. Effect estimates represent the change in PD odds ratio per one standard deviation increase in gene expression or methylation.